BR0213253A - Compound, use thereof, pharmaceutical composition, and methods for treating nuclear receptor-mediated conditions and type i diabetes, type ii diabetes, dyslipidemia, syndrome x (including metabolic syndrome, ie impaired glucose tolerance, insulin resistance , hypertriglyceridemia and / or obesity), cardiovascular disease (including atherosclerosis) or hypercholesteremia - Google Patents

Compound, use thereof, pharmaceutical composition, and methods for treating nuclear receptor-mediated conditions and type i diabetes, type ii diabetes, dyslipidemia, syndrome x (including metabolic syndrome, ie impaired glucose tolerance, insulin resistance , hypertriglyceridemia and / or obesity), cardiovascular disease (including atherosclerosis) or hypercholesteremia

Info

Publication number
BR0213253A
BR0213253A BR0213253-2A BR0213253A BR0213253A BR 0213253 A BR0213253 A BR 0213253A BR 0213253 A BR0213253 A BR 0213253A BR 0213253 A BR0213253 A BR 0213253A
Authority
BR
Brazil
Prior art keywords
diabetes
syndrome
type
methods
hypertriglyceridemia
Prior art date
Application number
BR0213253-2A
Other languages
Portuguese (pt)
Inventor
Per Sauerberg
Paul Stanley Bury
Lone Jeppesen
John Patrick Mogensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR0213253A publication Critical patent/BR0213253A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers

Abstract

"COMPOSTO, USO DO MESMO, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA O TRATAMENTO DE CONDIçõES MEDIADAS POR RECEPTORES NUCLEARES E DE DIABETES TIPO I, DIABETES TIPO II, DISLIPIDEMIA, SìNDROME X (INCLUINDO A SìNDROME METABóLICA, I.E. TOLERâNCIA PREJUDICADA à GLICOSE, RESISTêNCIA à INSULINA, HIPERTRIGLICERIDEMIA E/OU OBESIDADE), DOENçAS CARDIOVASCULARES (INCLUINDO ATEROSCLEROSE) OU HIPERCOLESTEREMIA". Uma classe inédita de derivados de ácido carboxílico, o uso destes compostos como composições farmacêuticas, composições farmacêuticas compreendendo os compostos e métodos de tratamento empregando estes compostos e composições. Os presentes compostos podem ser úteis no tratamento e/ou prevenção de condições mediadas por Receptores Ativados por Proliferador de Peroxissoma (PPAR)."COMPOSITION, USE OF THE SAME, PHARMACEUTICAL COMPOSITION, AND METHODS FOR TREATMENT MEDIATED BY NUCLEAR RECEPTORS AND TYPE I DIABETES, DYLIPHIDIA SYNDROME, INCLUDED TO THE SYNDROME, INCLUDING THE SYNDROME, INCLUDING THE SYNDROME INSULIN, HYPERTRIGLYCERIDEMIA AND / OR OBESITY), CARDIOVASCULAR DISEASES (INCLUDING ATHEROSCLEROSIS) OR HYPERCOLESTEREMIA ". An unprecedented class of carboxylic acid derivatives, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in treating and / or preventing Peroxisome Proliferator Activated Receptor (PPAR) -mediated conditions.

BR0213253-2A 2001-10-17 2002-10-15 Compound, use thereof, pharmaceutical composition, and methods for treating nuclear receptor-mediated conditions and type i diabetes, type ii diabetes, dyslipidemia, syndrome x (including metabolic syndrome, ie impaired glucose tolerance, insulin resistance , hypertriglyceridemia and / or obesity), cardiovascular disease (including atherosclerosis) or hypercholesteremia BR0213253A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101524 2001-10-17
PCT/DK2002/000692 WO2003033453A1 (en) 2001-10-17 2002-10-15 Dicarboxylic acid derivatives, their preparation and therapeutical use

Publications (1)

Publication Number Publication Date
BR0213253A true BR0213253A (en) 2004-10-26

Family

ID=8160773

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213253-2A BR0213253A (en) 2001-10-17 2002-10-15 Compound, use thereof, pharmaceutical composition, and methods for treating nuclear receptor-mediated conditions and type i diabetes, type ii diabetes, dyslipidemia, syndrome x (including metabolic syndrome, ie impaired glucose tolerance, insulin resistance , hypertriglyceridemia and / or obesity), cardiovascular disease (including atherosclerosis) or hypercholesteremia

Country Status (11)

Country Link
EP (1) EP1438283A1 (en)
JP (1) JP2005505616A (en)
KR (1) KR20050036876A (en)
CN (1) CN1571766A (en)
BR (1) BR0213253A (en)
CA (1) CA2462514A1 (en)
HU (1) HUP0401837A2 (en)
IL (1) IL161170A0 (en)
PL (1) PL370244A1 (en)
RU (1) RU2004114875A (en)
WO (1) WO2003033453A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003260282A1 (en) 2002-09-05 2004-03-29 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
US20050080115A1 (en) 2002-10-28 2005-04-14 Lone Jeppesen Novel compounds, their preparation and use
EP1558571B1 (en) * 2002-10-28 2010-06-02 High Point Pharmaceuticals, LLC Novel compounds useful in treating ppar mediated diseases
AU2003287912A1 (en) * 2002-12-20 2004-07-14 Novo Nordisk A/S Dicarboxylic acid derivatives as ppar-agonists
US7816385B2 (en) 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
FR2850969B1 (en) * 2003-02-12 2005-03-25 Genfit S A ACYLATED AMINOPROPANEDIOLS AND THE LIKE AND THEIR THERAPEUTIC USES
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
JP2007536343A (en) 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ Phenoxyacetic acid derivatives as PPAR agonists
EP1632245A1 (en) * 2004-09-02 2006-03-08 Technische Universität Dresden Medizinische Fakultät Carl Gustav Carus ICA512 couples insulin secretion and gene expression in Beta-cells
EP1899302B1 (en) 2005-06-30 2011-10-19 High Point Pharmaceuticals, LLC Phenoxy acetic acids as ppar delta activators
NZ568488A (en) 2005-12-22 2011-07-29 High Point Pharmaceuticals Llc Phenoxy acetic acids as PPAR delta activators
EP1999098A2 (en) * 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN103476258B (en) 2011-02-25 2017-04-26 默沙东公司 Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2898482A1 (en) 2013-02-22 2014-08-28 Linda L. Brockunier Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2913737A1 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN109200043A (en) * 2018-10-23 2019-01-15 华南农业大学 Application of the dicarboxylic acids (salt) in terms of reducing fat deposition and pre- preventing obesity
BR112023001048A2 (en) 2020-07-22 2023-04-04 Reneo Pharmaceuticals Inc CRYSTALLINE PPAR-DELTA AGONIST
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2331336A1 (en) * 1975-11-14 1977-06-10 Rolland Sa A OXY-4,4'BIS ACIDS (2-PHENOXY ALKANOCARBOXYLIC), THEIR DERIVATIVES AND THEIR APPLICATION AS A MEDICINAL PRODUCT
CA2114001A1 (en) * 1991-07-30 1993-02-18 Kunihiro Niigata Novel bisheterocyclic derivative or salt thereof
CN1396903A (en) * 2000-01-28 2003-02-12 诺沃挪第克公司 Novel compound, their preparation and use
CA2396372A1 (en) * 2000-01-28 2001-08-02 Novo Nordisk A/S Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity

Also Published As

Publication number Publication date
EP1438283A1 (en) 2004-07-21
PL370244A1 (en) 2005-05-16
CA2462514A1 (en) 2003-04-24
RU2004114875A (en) 2005-09-10
CN1571766A (en) 2005-01-26
HUP0401837A2 (en) 2004-12-28
JP2005505616A (en) 2005-02-24
KR20050036876A (en) 2005-04-20
WO2003033453A1 (en) 2003-04-24
IL161170A0 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
BR0213253A (en) Compound, use thereof, pharmaceutical composition, and methods for treating nuclear receptor-mediated conditions and type i diabetes, type ii diabetes, dyslipidemia, syndrome x (including metabolic syndrome, ie impaired glucose tolerance, insulin resistance , hypertriglyceridemia and / or obesity), cardiovascular disease (including atherosclerosis) or hypercholesteremia
BR0313825A (en) Compound, pharmaceutical composition, method for treating type 2 diabetes mellitus in a mammal, and, compound use
BR0010651A (en) Compound, use of a compound, pharmaceutical composition, and method for the treatment and / or prevention of disorders or diseases mediated by an antagonistic action of glucagon
BR0211414A (en) Compound, use thereof, pharmaceutical composition, and methods for treating and / or preventing nuclear receptor-mediated conditions and type i diabetes, type ii diabetes, impaired glucose tolerance, insulin resistance or obesity
BR0214305A (en) Heterocyclic Compounds and Methods of Use
PE20040655A1 (en) NEW THIOPHENE GLYCOSIDE DERIVATIVES, PROCEDURES FOR THEIR PREPARATION AND DRUGS CONTAINING THEM
EP1007039B1 (en) Novel heterocyclic analogs of diphenylethylene compounds
BR0011891A (en) Compound, pharmaceutical composition, use of a compound, methods for treating a hpparso-mediated disease or condition, to lower triglycerides in a patient, to treat type 2 diabetes, to decrease insulin resistance or to lower blood pressure in a patient , to decrease the fribogen levels in a patient, to decrease the ldlc in a patient and to change the particle size of the small dense ldl to normal dense ldl in a patient, and, use of an hpparso agonist
DE602006008576D1 (en) ANTIDIABETIC BICYCLIC COMPOUNDS
AR029605A1 (en) DERIVATIVES OF DIFENILUREA SUBSTITUTED WITH SULFONAMIDE, PHARMACEUTICAL COMPOSITION, USE OF THE SAME FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT AS AN ANTAGONIST OF IL-8 RECEPTORS, COMPOUNDS, INTERMEDIARIES, AND METHODS OF CONVERSES
BRPI0412380A (en) benzenesulfonylamino compounds and pharmaceutical compositions containing these
DE602005019043D1 (en) Glucagonone receptor agonists, their preparation and their therapeutic use
BR0107901A (en) Compound, pharmaceutical composition, method for treating illness, for treating and / or preventing conditions mediated by nuclear receptors, and for the treatment and / or prevention of diabetes and / or obesity, use of a compound, and, method for treating type i diabetes, type ii diabetes, impaired glucose tolerance, insulin resistance or obesity
ECSP056175A (en) N-ACILO NITROGEN HETEROCYCLES AS LEGANDS OF RECEPTORS ACTIVATED BY THE PEROXISOME PROLIFERATOR
PT1173197E (en) METABOLIC INTERVENTION WITH GLP-1, TO IMPROVE THE FUNCTION OF ISCHEMIC AND REPERFUNDED TISSUE
DE602006012725D1 (en) Glucagonone receptor agonists, their preparation and their therapeutic use
BRPI0407180A (en) Compound, pharmaceutical composition, methods for modulating a peroxisome proliferator-activated receptor, for treating or preventing a disease or condition, for lowering blood glucose in a mammal, for treating or preventing diabetes mellitus, cardiovascular disease, and syndrome x in a mammal. , and, use of a compound
DE602006019880D1 (en) USE OF THIENOPYRIDONE DERIVATIVES AS AMPK ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SE0500055D0 (en) Therapeutic agents 3
BRPI0412479A (en) compound, process for preparing a compound, pharmaceutical formulation, use of a compound, methods of treating and / or preventing lipid disorders (dyslipidemia) associated or not with insulin resistance, and atherosclerosis, and methods of treating and / or prophylaxis of cardiovascular disease, hypercholesterolemia, conditions associated with the need to improve reverse cholesterol transport, to decrease cholesterol absorption in the intestine, to increase HDL cholesterol levels, to lower cholesterol levels. ldl, inflammatory conditions, alzheimer's disease, atherosclerosis, type 2 diabetes, and conditions associated with the need to improve hdl function, and pharmaceutical composition
BR0016135A (en) Form of reduced particle size, use of a substance, pharmaceutical composition, methods for the treatment or prophylaxis of conditions associated with reduced insulin sensitivity and delipidemia, type II diabetes mellitus, hyperglycemia, hyperinsulinemia, arterial hypertension and / or obesity abdominal and process for the preparation of a compound
BRPI0412472A (en) compound, process for preparing a compound, pharmaceutical formulation, use of a compound, methods of treating and / or preventing lipid disorders (dyslipidemia) associated or not with insulin resistance, and atherosclerosis, methods of treatment and / or prophylaxis of cardiovascular disease, hypercholesterolemia, conditions associated with the need to improve reverse cholesterol transport, and to decrease cholesterol absorption in the intestine, to increase HDL cholesterol levels, to lower cholesterol levels. ldl, inflammatory conditions, alzheimer's disease, type 2 diabetes arteriosclerosis, conditions associated with the need to improve hdl function, and pharmaceutical composition
BR9813801A (en) Compound, pharmaceutical composition, and processes for the treatment, control, or prevention, in a mammal, of diabetes mellitus, hyperglycemia, hyperlipidemia, obesity, hypercholesterolemia, and, hypertriglyceridemia.
HK1083021A1 (en) Substituted arylalcanoic acid derivatives as ppar pan agonists with potent antihyperglycemic and antihyperlipidemic activity
PE20080834A1 (en) DIARYLIC ETHER DERIVATIVES ANTAGONISTS OF OPIOID RECEPTORS

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]